{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:07:11Z","timestamp":1792112831977,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T00:00:00Z","timestamp":1474934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01MH102215"],"award-info":[{"award-number":["R01MH102215"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychiatr Q"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11126-016-9468-5","type":"journal-article","created":{"date-parts":[[2016,9,27]],"date-time":"2016-09-27T17:36:52Z","timestamp":1474997812000},"page":"545-552","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Blood Pressure and Heart Rate Changes During Clozapine Treatment"],"prefix":"10.1007","volume":"88","author":[{"given":"Sarah M.","family":"Norman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelli M.","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany A.","family":"DiPaula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro A.","family":"Jose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Kitchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna L.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,27]]},"reference":[{"key":"9468_CR1","doi-asserted-by":"publisher","first-page":"e31","DOI":"10.4088\/JCP.13078tx2c","volume":"75","author":"A Abi-Dargham","year":"2014","unstructured":"Abi-Dargham A. Schizophrenia: overview and dopamine dysfunction. Journal of Clinical Psychiatry 2014;75:e31.","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"9468_CR2","first-page":"1","volume":"71","author":"DL Kelly","year":"2010","unstructured":"Kelly DL, McMahon RP, Liu F, Love RC, Wehring HJ, Shim JC, et al. Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. Journal of Clinical Psychiatry 2010;71(3):1\u2013478.","journal-title":"Journal of Clinical Psychiatry"},{"key":"9468_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010;36:71\u201393.","journal-title":"Schizophrenia Bulletin"},{"key":"9468_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S0006-3223(99)00029-3","volume":"46","author":"RR Conley","year":"1999","unstructured":"Conley RR, Tamminga CA, Kelly DL, Richardson CM. Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biological Psychiatry 1999;46:73\u201377.","journal-title":"Biological Psychiatry"},{"key":"9468_CR5","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/ajp.156.7.990","volume":"156","author":"K Wahlbeck","year":"1999","unstructured":"Wahlbeck K, Cheine M, Essali A, Adams C. Evidence of clozapine\u2019s effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. American Journal of Psychiatry 1999;156:990\u201399.","journal-title":"American Journal of Psychiatry"},{"key":"9468_CR6","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1176\/appi.ajp.158.4.518","volume":"158","author":"M Chakos","year":"2001","unstructured":"Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. American Journal of Psychiatry 2001;158:518\u2013526.","journal-title":"American Journal of Psychiatry"},{"key":"9468_CR7","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1136\/bmj.327.7409.288","volume":"327","author":"J Moncrieff","year":"2003","unstructured":"Moncrieff J. Antidepressant prescribing and suicide: analysis is misleading. British Medical Journal 2003;327:288; author reply 289.","journal-title":"British Medical Journal"},{"key":"9468_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-9964(01)00212-2","volume":"56","author":"A Tuunainen","year":"2002","unstructured":"Tuunainen A, Wahlbeck K, Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophrenia Research 2002;56:1\u201310.","journal-title":"Schizophrenia Research"},{"key":"9468_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/026988110001400411","volume":"14","author":"DM Taylor","year":"2000","unstructured":"Taylor DM and Duncan-McConnell D. Refractory schizophrenia and atypical antipsychotics. Journal of Psychopharmacology 2000;14:409\u2013418.","journal-title":"J Psychopharmacol"},{"key":"9468_CR10","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382:951\u2013962.","journal-title":"Lancet"},{"key":"9468_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","volume":"163","author":"JP McEvoy","year":"2006","unstructured":"McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 2006;163:600\u2013610.","journal-title":"American Journal of Psychiatry"},{"key":"9468_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1093\/schbul\/sbj067","volume":"32","author":"SW Lewis","year":"2006","unstructured":"Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophrenia Bulletin 2006;32:715\u2013723.","journal-title":"Schizophrenia Bulletin"},{"key":"9468_CR13","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1111\/j.1600-0447.2004.00450.x","volume":"111","author":"JM Haro","year":"2005","unstructured":"Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, Jones BP, et al. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scandinavica 2005;111:220\u2013231.","journal-title":"Acta Psychiatrica Scandinavica"},{"issue":"1","key":"9468_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.3371\/CSRP.1.1.8","volume":"1","author":"D Kelly","year":"2007","unstructured":"Kelly D, Kreyenbuhl J, Buchanan R, Malhotra A. Why not clozapine? Clinical Schizophrenia & Related Psychoses 2007;1(1):92\u201395.","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"issue":"7","key":"9468_CR15","first-page":"1","volume":"68","author":"M Curto","year":"2016","unstructured":"Curto M, Girardi N, Lionetto L, Giuseppino CM, Ferracuti S, Baldessarini R. Systematic review of clozapine cardiotoxicity. Current Psychiatry Reports 2016;68(7):1\u201318.","journal-title":"Current Psychiatry Reports"},{"issue":"6","key":"9468_CR16","doi-asserted-by":"publisher","first-page":"751","DOI":"10.4088\/JCP.09m05402yel","volume":"72","author":"YM Bai","year":"2011","unstructured":"Bai YM, Lin C, Chen J, Chen TT, Su T, Chou P. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study. Journal of Clinical Psychiatry 2011;72(6):751\u201356.","journal-title":"Journal of Clinical Psychiatry"},{"key":"9468_CR17","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1176\/ajp.153.3.435-a","volume":"153","author":"TP George","year":"1996","unstructured":"George TP, Winther LC. Hypertension after initiation of clozapine. American Journal of Psychiatry 1996;153:1368\u20131369.","journal-title":"American Journal of Psychiatry"},{"key":"9468_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/194927","author":"J Sara","year":"2013","unstructured":"Sara J, Jenkins M, Chohan T, Jolly K, Shepard L, Gandhi NY, et al. Clozapine use presenting with pseudopheochromocytoma in a schizophrenic patient: a case report. Case Reports Endocrinology 2013. doi: 10.1155\/2013\/194927 .","journal-title":"Case Reports Endocrinology"},{"key":"9468_CR19","doi-asserted-by":"publisher","first-page":"889","DOI":"10.3109\/00048679709065519","volume":"31","author":"JKY Li","year":"1997","unstructured":"Li JKY, Yeung VT, Leung CM, Chow CC, Ko GT, So WY, et al. Clozapine: a mimicry of phaeochromocytoma. Australian and New Zealand Journal of Psychiatry 1997;31:889\u2013891. doi: 10.3109\/00048679709065519 .","journal-title":"Australian and New Zealand Journal of Psychiatry"},{"key":"9468_CR20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1097\/JCP.0000000000000044","volume":"34","author":"EJ Hoorn","year":"2014","unstructured":"Hoorn EJ, van der Poel MF. Hypokalemic hypertension related to clozapine: a case report. J Clin Psychopharmacol 2014;34:390\u2013392.","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"9468_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.4314\/ajpsy.v14i5.9","volume":"14","author":"O Akinsola","year":"2011","unstructured":"Akinsola O, Ong K. Pseudophaeochromocytoma associated with clozapine therapy: a case report. African Journal of Psychiatry 2011;14:406\u2013408.","journal-title":"African Journal of Psychiatry"},{"key":"9468_CR22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5694\/j.1326-5377.1997.tb140118.x","volume":"166","author":"LM Ennis","year":"1997","unstructured":"Ennis LM and Parker RM. Paradoxical hypertension associated with clozapine. Medical Journal of Australia 1997;166:278.","journal-title":"Medical Journal of Australia"},{"key":"9468_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1176\/ajp.151.11.1706","volume":"151","author":"S Gupta","year":"1994","unstructured":"Gupta S, Rajaprabhakaran R. Paradoxical hypertension associated with clozapine. American Journal of Psychiatry 1994;151:148.","journal-title":"American Journal of Psychiatry"},{"key":"9468_CR24","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1136\/bmj.322.7296.1213","volume":"322","author":"AJ Krentz","year":"2001","unstructured":"Krentz AJ, Mikhail S, Cantrell P, Hill GM. Drug Points: pseudophaeochromocytoma syndrome associated with clozapine. British Medical Journal 2001;322:1213.","journal-title":"British Medical Journal"},{"key":"9468_CR25","unstructured":"American Psychiatric Association, ed. Diagnostic and statistical manual of mental disorders: DSM-IV. 4th ed. Washington (DC): American Psychiatric Association; 1994"},{"issue":"5","key":"9468_CR26","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507\u2013520.","journal-title":"JAMA"},{"key":"9468_CR27","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1016\/j.hrthm.2015.09.019","volume":"13","author":"WC Members","year":"2016","unstructured":"Members WC, Page RL, Joglar JA, Caldwell MA, Calkins H, Conti JB, et al. 2015 ACC\/AHA\/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm 2016;13:e136\u2013e221.","journal-title":"Heart Rhythm."},{"key":"9468_CR28","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4088\/JCP.v65n0514","volume":"65","author":"DC Henderson","year":"2004","unstructured":"Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. Journal of Clinical Psychiatry 2004;65:686\u2013689.","journal-title":"Journal of Clinical Psychiatry"},{"key":"9468_CR29","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1080\/15622970801910399","volume":"10","author":"YS Woo","year":"2009","unstructured":"Woo YS, Kim W, Chae J, Yoon B, Bahk W. Blood pressure changes during clozapine or olanzapine treatment in Korean schizophrenic patients. World Journal of Bioliogical Psychiatry 2009;10:420\u2013425.","journal-title":"World Journal of Bioliogical Psychiatry"},{"key":"9468_CR30","first-page":"PI19","volume":"10","author":"LK Oyewumi","year":"2004","unstructured":"Oyewumi LK, Cernovsky ZZ, Freeman DJ. Autonomic signs and dosing during the initial stages of clozapine therapy. Med Sci Monit 2004;10:PI19\u201323.","journal-title":"Medical Science Monitor"},{"key":"9468_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1192\/bjp.179.2.167","volume":"179","author":"H Cohen","year":"2001","unstructured":"Cohen H, Loewenthal U, Matar M, Kotler M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. British Journal of Psychiatry 2001;179:167\u2013171.","journal-title":"British Journal of Psychiatry"},{"key":"9468_CR32","first-page":"139","volume":"21","author":"RS Shiwach","year":"1998","unstructured":"Shiwach RS. Treatment of clozapine induced hypertension and possible mechanisms. Clinical Neuropharmacology 1998;21:139\u2013140.","journal-title":"Clinical Neuropharmacology"},{"key":"9468_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","volume":"68","author":"E Richelson","year":"2000","unstructured":"Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sciences 2000;68:29\u201339.","journal-title":"Life Sciences"},{"key":"9468_CR34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","volume":"462","author":"HO Kalkman","year":"2003","unstructured":"Kalkman HO, Loetscher E. alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs. European Journal of Pharmacology 2003;462:33\u201340.","journal-title":"European Journal of Pharmacology"},{"key":"9468_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/0165-1781(93)90017-B","volume":"46","author":"M Davidson","year":"1993","unstructured":"Davidson M, Kahn R, Stern RG, Hirschowitz J, Apter S, Knott P, et al. Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res 1993;46:151\u2013163.","journal-title":"Psychiatry Research"},{"key":"9468_CR36","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1161\/01.HYP.0000198427.96225.36","volume":"47","author":"MJ Bek","year":"2006","unstructured":"Bek MJ, Wang X, Asico LD, Jones JE, Zheng S, Li X, et al. Angiotensin-II type 1 receptor-mediated hypertension in D4 dopamine receptor-deficient mice. Hypertension 2006;47:288\u2013295.","journal-title":"Hypertension"},{"key":"9468_CR37","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"HH Van Tol","year":"1991","unstructured":"Van Tol HH, Bunzow JR, Guan HC, Sunahara RK, Seeman P, Niznik HB, et al. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991;350:610\u2013614.","journal-title":"Nature"},{"key":"9468_CR38","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/01.HYP.38.3.303","volume":"38","author":"XX Li","year":"2001","unstructured":"Li XX, Bek M, Asico LD, Yang Z, Grandy DK, Goldstein DS, et al. Adrenergic and endothelin B receptor-dependent hypertension in dopamine receptor type-2 knockout mice. Hypertension 2001;38:303\u2013308.","journal-title":"Hypertension"}],"container-title":["Psychiatric Quarterly"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11126-016-9468-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-016-9468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11126-016-9468-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T07:55:29Z","timestamp":1692518129000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11126-016-9468-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,27]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["9468"],"URL":"https:\/\/doi.org\/10.1007\/s11126-016-9468-5","relation":{},"ISSN":["0033-2720","1573-6709"],"issn-type":[{"value":"0033-2720","type":"print"},{"value":"1573-6709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,27]]},"assertion":[{"value":"27 September 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Deanna L. Kelly is on the Advisory Board for Stigma Project funded by Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}